Skip to content

Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability

Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01439672
Acronym
BPK005
Enrollment
35
Registered
2011-09-23
Start date
2010-08-31
Completion date
2012-03-31
Last updated
2016-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

Type 1 Diabetes Mellitus

Brief summary

This protocol will investigate physiological parameters including insulin sensitivity and counterregulatory function using a mixed meal test and induced hypoglycemia in subjects with type I diabetes.

Detailed description

The principal idea of the proposed research is: in order to be successful, closed-loop control of glucose in diabetes must adapt to individual physiologic characteristics and to the behavioral profile of each person. We propose to build a system that will use observers of patients' behavior and metabolic state and control modules that are responsible for insulin delivery and hypoglycemia prevention. In this phase of the project, we will investigate relationships of insulin sensitivity and impaired counterregulation with blood glucose variability, aiming to develop algorithmic physiology observers, which will track specific parameters of glucose variability and recurrent hypoglycemia as markers of change in a person's insulin sensitivity and counterregulatory ability.

Interventions

DIETARY_SUPPLEMENTMixed meal and insulin challenge

The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \ 100mg/dl at 1100.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Type I diabetes mellitus (TIDM) (as defined by the American Diabetes Association criteria or judgment of a physician) for at least two years prior to the enrollment in the study. * Use of an insulin pump to treat their diabetes for at least six months prior to the study. * Ability to use a bolus calculator function with the current insulin pump with pre-defined parameters for glucose goal, carbohydrate ratio, and insulin sensitivity factor. * Age 21 - 64 years. Adults age 65 and over are likely to have medical exclusions for the follow-up Phase 2 study, which involves induced hypoglycemia. * Completed Phase 1 of the Institutional Review Board (IRB) #14956 Development of a Behavioral Observer for Type 1 Diabetes Mellitus * Willingness to use lispro (Humalog) insulin two days prior to and during inpatient admission. * Willingness to perform Self-Monitoring Blood Glucose (SMBG) 4 times per day at times before meals and bedtime. * Demonstration of proper mental status and cognition for completion of the study.

Exclusion criteria

* Pregnancy * Psychiatric disorders that would interfere with study tasks (e.g. mental retardation, substance abuse) * History of a systemic deep tissue infection with methicillin-resistant staph aureus or Candida albicans * Known bleeding diathesis or dyscrasia * Active enrollment in another clinical trial * Medical condition that would make operating an insulin pump difficult (e.g. blindness, severe arthritis, extensive scar tissue at sites where devices are inserted). * Anemia (hematocrit \<36% \[females\], \<38% \[males\]), * Allergy or adverse reaction to lispro (Humalog) insulin * Conditions which may increase the risk of induced hypoglycemia such as symptomatic heart disease, congestive heart failure, history of a cerebrovascular event, atrial fibrillation, renal insufficiency (creatinine \>1.5) or uncontrolled hypertension (resting blood pressure \>140/90).

Design outcomes

Primary

MeasureTime frameDescription
Insulin Sensitivity24 hoursMeasure insulin sensitivity following a mixed meal across admissions. Insulin sensitivity was measured based on the minimal model of glucose kinetics using plasma glucose and insulin obtained frequently (approximately every 5-15 minutes) in response to mixed meal challenge.

Countries

United States

Participant flow

Participants by arm

ArmCount
Insulin Sensitivity
Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity. Mixed meal and insulin challenge: The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \ 100mg/dl at 1100.
11
Total11

Baseline characteristics

CharacteristicInsulin Sensitivity
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
Gender
Female
4 Participants
Gender
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
2 / 35
serious
Total, serious adverse events
0 / 35

Outcome results

Primary

Insulin Sensitivity

Measure insulin sensitivity following a mixed meal across admissions. Insulin sensitivity was measured based on the minimal model of glucose kinetics using plasma glucose and insulin obtained frequently (approximately every 5-15 minutes) in response to mixed meal challenge.

Time frame: 24 hours

ArmMeasureValue (MEAN)
Insulin SensitivityInsulin Sensitivity3.37*10^-4 1/min per uU/mL

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026